- GlaxoSmithKline has bought 10% stake worth £ 130 million in CureVac.
- Stake of 10% is part of deal between two companies that could eventually be worth more than £ 800 million.
The British pharmaceutical company GlaxoSmithKline (GSK) has bought a 10% stake in a German biotech company called CureVac. CureVac is a key player in the global race for a coronavirus....
Tags : GlaxoSmithKline, GSK, CureVac, coronavirus, COVID-19, messenger ribonucleic acid, mRNA, vaccine, Tübingen, UK, Germany, United Kingdom,